Attorney general forces infectious diseases society of America to redo lyme guidelines due to flawed development process

Journal of Medical Ethics

Volumn 35, Issue 5, 2009, Pages 283-288

  Johnson, L ^a   Stricker, R B ^b  

^a California Lyme Disease Association   (United States)

^b International Lyme and Associated Diseases Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; ETHICS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; LAW; LEGAL ASPECT; LYME DISEASE; MEDICAL SOCIETY; PRACTICE GUIDELINE; UNITED STATES;

ANTITRUST LAWS; CONFLICT OF INTEREST; CONNECTICUT; HEALTH POLICY; HUMANS; LYME DISEASE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; SOCIETIES, MEDICAL; UNITED STATES;

EID: 69649098938     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/jme.2008.026526     Document Type: Article

References (17)

1. Johnson LB, Stricker RB. Treatment of Lyme disease-a medicolegal assessment. Expert Rev Anti-infect Ther 2004;2:533-57.
2. Stolberg S. Study says clinical guides often hide ties of doctors. New York Times. 6 Feb 2002; National Desk. www.nytimes.com/2002/02/06/health/06DRUG.html (accessed 9 Mar 2009).
3. Integrity in Science. Integrity in Science Watch Week of 03/10/2008. IOM urged to recommend conflict-free zone for medicine. www.cspinet.org/integrity/watch/200803101.html (accessed 9 Mar 2009).
4. Stricker RB. Lymerix® risks revisited. Microbe 2008;3:1-2.
5. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-134. (See appendix A for details of competing interests.)
6. Feder HM, Johnson BJB, O'Connell S, et al, the Ad Hoc International Lyme Disease Group. A critical appraisal of "chronic Lyme disease". N Engl J Med 2007;357:1422-30. Erratum in: N Engl J Med 2008;358:1084. (See appendix A for details of competing interests.)
7. Porwancher RB, Bockenstedt L, Dattwyler R, et al. Lyme Wars: Critique misses mark. BMJ rapid response 30 Nov 2007. www.bmj.com/cgi/eletters/335/7628/1008 (accessed 9 Mar 2009). (See appendix A for details of competing interests.)
8. Center for Biotechnology. Companies developed. Brook Biotechnologies. http://www.biotech.sunysb.edu/industDev/comp-dev.html (accessed 9 Mar 2009). (See appendix A for details of competing interests.)
9. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 2007;69:91-102. (See appendix A for details of competing interests.)
10. Abbott A. Uphill struggle. Nature 2006;439:524-5. (See appendix A for details of competing interests).
11. Saul S. Unease on industry's role in hypertension debate. New York Times. 20 May 2006. www.nytimes.com/2006/05/20/business/20hyper.html?ex=1148788800&en=c743a665286103ef&ei=5070&emc=eta1 (accessed 9 Mar 2009).
12. Ferrette C. Lyme disease expert defends research. Journal News. 6 May 2008. http://m.lohud.com/news.jsp?key=76504 (accessed 14 Mar 2009).
13. Eddy DM. Three battles to watch in the 1990s. JAMA 1993;270:520-6.
14. Eddy DM. Clinical decision making: from theory to practice, practice policies-what are they? JAMA 2000;263:877-8.
15. Connecticut Attorney General's Office. Attorney General's investigation reveals flawed Lyme disease guideline process, IDSA agrees to reassess guidelines, install independent arbiter. 1 May 2008. http://www.ct.gov/ag/cwp/view.asp?a=2795&q=414284 (accessed 9 Mar 2009).
16. Stricker RB, Johnson LB. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review). Neurology 2008;70:1719.
17. Landers SJ. Lyme treatment accord ends antitrust probe. American Medical News 9 June 2008. http://www.ama-assn.org/amednews/2008/06/09/hlsa0609.htm (accessed 9 Mar 2009).